Minority researchers receive AACR awards

December 30, 2004

PHILADELPHIA -- Each year, the American Association for Cancer Research (AACR) presents awards to minority scholars who have made an impact in cancer research, and show potential to continue to do so in the future.

AACR Minority Scholar Awards in Cancer Research go to full-time graduate or medical students, residents, clinical or postdoctoral fellows, or junior faculty members. Recipients of the awards are chosen on the stipulation that applicants fit the National Cancer Institute definition of groups traditionally underrepresented in cancer and biomedical research. These groups include African Americans, Alaskan Natives, Hispanics, Native Americans, and Native Pacific Islanders.

For Fall 2004 AACR Special Conferences, 44 awards totaling some $80, 000 have been granted. The funds allow early career scientists to attend an AACR Special Conference.

Grants for these awards are provided by the Comprehensive Minority Biomedical Branch of the National Cancer Institute. Scientists are nominated and receive the awards based on their qualifications, references from mentors, and potential professional benefit. Awardees are chosen by an Advisory Committee of the AACR.

Fall 2004 conferences included: Advances in Proteomics in Cancer Research, October 6-10, Key Biscayne, Fla.; Frontiers in Cancer Prevention Research, October 16-20, Seattle, Wash.; The Role of Telomeres and Telomerase in Cancer, November 3-7, San Francisco, Calif.; Chromatin, Chromosomes, and Cancer Epigenetics, November 10-14, Waikoloa, Hawaii; Basic, Translational, and Clinical Advances in Prostate Cancer, November 17-21, Bonita Springs, Fla.; Cell Cycle and Cancer: Pathways and Therapies, December 1-5, Fort Lauderdale, Fla.

Winners of Minority Scholar Awards for participation in the Fall 2004 AACR Special Conferences are listed below.

Advances in Proteomics in Cancer Research, October 6-10, Key Biscayne, Fla. Chevonne D. Eversley, B.S., University of North Carolina, Chapel Hill, N.C.

Frontiers in Cancer Prevention Research, October 16-20, Seattle, Wash.The Role of Telomeres and Telomerase in Cancer, November 3-7, San Francisco, Calif.
Chromatin, Chromosomes, and Cancer Epigenetics, November 10-14, Waikoloa, Hawaii
Basic, Translational, and Clinical Advances in Prostate Cancer, November 17-21, Bonita Springs, Fla.
Cell Cycle and Cancer: Pathways and Therapies, December 1-5, Fort Lauderdale, Fla.
-end-
Founded in 1907, the American Association for Cancer Research is a professional society of more than 24,000 laboratory, translational, and clinical scientists engaged in all areas of cancer research in the United States and in more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication, and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. AACR's Annual Meeting attracts more than 15,000 participants who share new and significant discoveries in the cancer field. Specialty meetings, held throughout the year, focus on the latest developments in all areas of cancer research.

American Association for Cancer Research

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.